Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proof of acute cardiac ischemia by elevated serum Troponin T-hs levels \> 14 pg/nl~* Proof of myocardial dyskinesia with functional echocardiography (speckle tracking)~* Stable angina pectoris \>/= CCS II in patient history~* Stabilized (i.e. normalized vital parameters) patients after coronary angioplasty or angiography~* Coronary angioplasty or angiography not older than 24 hours~* Written informed consent~* Established standard therapy for coronary artery disease (i.e. Beta-Blocker, ACE-Inhibitor or AT1-Inhibitor, ASS, Clopidogrel, Statins)~Exclusion Criteria:~* Patients younger than 18 years of age~* Acute cardio-pulmonary decompensation~* Middle and high grade liver insufficiency (Child-Pugh Score B and C)~* High grade renal insufficiency (Creatinine-Clearance \< 30 ml/min)~* Concomitant treatment with potent inhibitors of CYP3A4~* Concomitant administration of class Ia (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics, except for amiodarone~* Concomitant administration of \> 20 mg simvastatin/day~* Patients with heart failure classification NYHA III and NYHA IV~* Homeless patients and drug-addicted patients~* Pregnant and/or breast-feeding women~* Treatment with Ranolazine prior to enrolment in RIMINI-Trial~* Allergy against Ranolazine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
- No additional medication (Type: NO_INTERVENTION): No additional medication - control group

Based on this trial design, predict the completion outcome and termination type (if applicable).